The Natural History of Benign Thyroid Nodules

Durante, Cosimo; Costante, Giuseppe; Lucisano, Giuseppe; Bruno, Rocco; Meringolo, Domenico; Paciaroni, Alessandro; Puxeddu, Efisio; Torlontano, Massimo; Tumino, Dario; Attard, Marco; Lamartina, Livia; Nicolucci, Antonio; Filetti, Sébastiano

doi:10.1001/jama.2015.0956

Cited by 383 publications

(279 citation statements)

References 31 publications

Supporting

Mentioning

234

Contrasting

Unclassified

Order By: Relevance

“…At our institution the malignancy rate among nodules with documented growth is quite low (i.e. 1-2%), in agreement with other papers reporting thyroid lesions followed-up after an initial benign assessment [21][22][23][24]. Finally, in our series PTC/ FTC ratio was 72:1 (216/3 cases).…”

Section: Discussionsupporting

confidence: 91%

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

et al. 2016

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

et al. 2016

View full text Add to dashboard Cite

“…This creates an important clinical dilemma as thyroid nodules are very common in 50-67% of the population, and more than 90% are benign (Mazzaferri 1992, Hegedus 2004, Popoveniuc & Jonklaas 2012, Durante et al 2015. Detection rates of thyroid nodules are increasing due to widespread use of imaging modalities in advanced health care systems (Cramer et al 2010, Popoveniuc & Jonklaas 2012.…”

Section: :11mentioning

confidence: 99%

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Nieto¹,

Boelaert²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Differentiated thyroid cancer is the most common endocrine malignancy and the incidence is increasing rapidly worldwide. Appropriate diagnosis and post-treatment monitoring of patients with thyroid tumours are critical. Fine needle aspiration cytology remains the gold standard for diagnosing thyroid cancer, and although there have been significant refinements to this technique, diagnostic surgery is often required for patients suspected to have malignancy. Serum thyroid-stimulating hormone (TSH) is higher in patients with malignant thyroid nodules than in those with benign disease, and TSH is proportionally increased in more aggressive tumours. Importantly, we have shown that the pre-operative serum TSH concentration independently predicts the presence of malignancy in subjects presenting with thyroid nodules. Establishing the use of TSH measurements in algorithms identifying high-risk thyroid nodules in routine clinical practice represents an exciting, cost-efficient and non-invasive approach to optimise thyroid cancer diagnosis. Binding of TSH to receptors on thyrocytes stimulates a number of growth promoting pathways both in normal and malignant thyroid cells, and TSH suppression with high doses of levothyroxine is routinely used after thyroidectomy to prevent cancer recurrence, especially in high-risk tumours. This review examines the relationship between serum TSH and thyroid cancer and reflects on the clinical potential of TSH measurements in diagnosis and disease monitoring.

show abstract

“…Durante et al reported that 15.4% (n=153) of the benign nodules grew using the ATA criteria (9). Only two malignancies were detected from these nodules after second TFNAB.…”

Section: Discussionmentioning

confidence: 99%

Cytologic Comparison Between Growing and Non-growing Benign Thyroid Nodules Evaluated Using Two Different Growth Criteria

Yalcin¹,

Yeşil²,

Akıncı³

et al. 2018

Turk J Endocrinol Metab

View full text Add to dashboard Cite

The Natural History of Benign Thyroid Nodules

Cited by 383 publications

References 31 publications

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Cytologic Comparison Between Growing and Non-growing Benign Thyroid Nodules Evaluated Using Two Different Growth Criteria

Contact Info

Product

Resources

About